التفاصيل البيبلوغرافية
| العنوان: |
Bortezomib, Thalidomide, and Dexamethasone as Induction Therapy for Patients With Symptomatic Multiple Myeloma. |
| المؤلفون: |
Kaufman, Jonathan L.1 jlkaufm@emory.edu, Nooka, Ajay1, Vrana, Mark2, Gleason, Charise1, Heffner, L. Thompson1, Lonial, Sagar1 |
| المصدر: |
Cancer (0008543X). 7/1/2010, Vol. 116 Issue 13, p3143-3151. 9p. 4 Charts, 3 Graphs. |
| مصطلحات موضوعية: |
*MULTIPLE myeloma, *THALIDOMIDE, *DEXAMETHASONE, *CELL transplantation, *AUTOTRANSPLANTATION, *PATIENTS |
| مستخلص: |
The article focuses on a study which assessed the efficacy of bortezomib, thalidomide and dexamethasone (BTD) as induction therapy for patients with multiple myeloma (MM). The study included patients with MM who were eligible for autologous stem cell transplantation (ASCT). Overall response rate (ORR) was 91 percent, while ORR following ASCT was 100 percent. Study authors concluded that BTD is effective and well tolerated as induction for MM patients who were eligible for ASCT. |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder